Audrey Lasry

Thrilled to share the second part of my postdoc in the #aifantislab out now on Biorxiv: biorxiv.org/content/10.648… this is in collaboration with the amazing @BettinaNadorp @sanamloghavi and led by @iannisaifantis1 and @AkEisfeld

@ewang2323 @ScienceTM @spicyscientist @Cuijuan3 Congrats Eric!

Excited to share our lab’s second paper published in @ScienceTM led by @spicyscientist and @Cuijuan3! 1/ science.org/eprint/W9M5JXK…

🚀 New preprint! The Human Cytokine Dictionary - 9.7M cells, 12 donors, 90 cytokines - our largest human single-cell perturbation atlas yet. Users can map cytokine activity in their own data. Huge thanks to Lukas, Sören, Larsen, Parse Bio & Seelig lab! 🔗 biorxiv.org/content/10.648…

and if you’re like us and are thinking about extramedullary AML a lot these days.. you should check out our preprint 🤩 biorxiv.org/content/10.648…

Excited about today's presentations in #leukemia #lymphoma and #myeloma at #ASH25 #ASH2025 by our NYU @Perlmutter_CC @nyulangone @NYULH_DeptofMed @nyugrossman faculty and trainees, including these 3 highlighted below!

Multiomic characterization, early detection, and therapeutic targeting of myeloid sarcoma biorxiv.org/content/10.648… #biorxiv_cancer

Commendable work by @iannisaifantis1 Lab and incredible team @sanamloghavi on MS and RAS pathway mutations in AML! Will check out the full paper after #ASH25

@anandbmdphd @BettinaNadorp @sanamloghavi @iannisaifantis1 @AkEisfeld Thanks!

@audrey_lasry @BettinaNadorp @sanamloghavi @iannisaifantis1 @AkEisfeld Congratulations @audrey_lasry ! Sounds super interesting and can’t wait to read it

Thrilled to share the second part of my postdoc in the #aifantislab out now on Biorxiv: biorxiv.org/content/10.648… this is in collaboration with the amazing @BettinaNadorp @sanamloghavi and led by @iannisaifantis1 and @AkEisfeld

Overall, our work demonstrates that RAS activation is a hallmark of myeloid sarcomas, and we suggest RAS inhibition as a therapeutic strategy for myeloid sarcoma patients

Treatment of these mice with RAS inhibitor RMC-7977 extends survival and reduces extramedullary tumor burden